All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health, GSK, Sumitomo Pharma, and supported through educational grants from Bristol Myers Squibb and Incyte. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Long-term ropeginterferon alfa‑2b HIDAT treatment in PV: Phase II results
Results from the 36-month follow-up of a single-arm, multicenter, phase II trial (NCT05485948) evaluating ropeginterferon alfa‑2b under a higher initial dose and accelerated titration (HIDAT) regimen in 49 patients with hydroxyurea (HU)-intolerant polycythemia vera (PV) were published in Blood Advances by Suo et al. Endpoints included reduction in JAK2V617F variant allele frequency (VAF) from baseline, complete molecular response (CMR) rate, partial molecular response (PMR) rate, complete hematologic remission (CHR) rate, event-free survival (EFS), and safety.
Key data: At 36 months, 97.7% of patients exhibited absolute reductions in JAK2V617F VAF from baseline. A molecular response was observed in 86% of patients, with 34.9% demonstrating CMR and 51.2% demonstrating PMR. CHR rates remained high from 27 months to 36 months (84.1% to 75.0%). Kaplan–Meier analysis showed 100% EFS in patients achieving CMR vs ~70% in those without molecular response (p = 0.035). Treatment-emergent adverse events (TEAEs) occurred in 81.8% of patients, none of which exceeded Grade 3 (9.1%, Grade 3 TEAEs).
Key learning: The HIDAT regimen of ropeginterferon alfa‑2b demonstrated sustained CHR rates, high CMR rates, and favorable tolerability in patients with HU-intolerant PV at 3 years
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
